Cover Image

Post-treatment human papillomavirus antibody kinetics in cervical cancer patients

Antibodies to the E6 and E7 oncoproteins of high-risk human papillomavirus (HPV) types are strongly associated with HPV-driven cancer, while antibodies against the capsid protein L1 are considered cumulative exposure markers. To test the hypothesis that L1 antibody levels are stable over time, where...

Full description

Saved in:
Bibliographic Details
Main Authors: Piontek, Till (Author) , Harmel, Christoph (Author) , Pawlita, Michael (Author) , Carow, Katrin (Author) , Börner, Juliane (Author) , Runnebaum, Ingo B. (Author) , Dürst, Matthias (Author) , Graw, Frederik (Author) , Waterboer, Tim (Author)
Format: Article (Journal)
Language:English
Published: 27 May 2019
In: Philosophical transactions of the Royal Society of London. Series B, Biological sciences
Year: 2019, Volume: 374, Issue: 1773, Pages: 1-11
ISSN:2054-0280
DOI:10.1098/rstb.2018.0295
Online Access:Verlag, Volltext: https://doi.org/10.1098/rstb.2018.0295
Get full text
Author Notes:Till Piontek, Christoph Harmel, Michael Pawlita, Katrin Carow, Juliane Schröter, Ingo B. Runnebaum, Matthias Dürst, Frederik Graw and Tim Waterboer
Description
Summary:Antibodies to the E6 and E7 oncoproteins of high-risk human papillomavirus (HPV) types are strongly associated with HPV-driven cancer, while antibodies against the capsid protein L1 are considered cumulative exposure markers. To test the hypothesis that L1 antibody levels are stable over time, whereas E6 and E7 levels undergo decay after cervical cancer (CxCa) treatment, we performed multiplex serology for HPV16 and 18 antigens E6, E7 and L1 in a post-treatment study of 184 patients with invasive CxCa that were characterized with a median follow-up time of 725 days, and 2–12 sera per patient. ...
Item Description:Online veröffentlicht am 8. April 2019
Gesehen am 14.08.2019
Physical Description:Online Resource
ISSN:2054-0280
DOI:10.1098/rstb.2018.0295

Similar Items